New systemic treatment possibilities in non-small cell lung cancer

In recent years a tremendous development was seen in the treatment of non-small cell lung cancer. Based on the knowledge of the heterogeneity of lung cancer the results of precision medicine can be used. Several drugable mutations with effective treatment possibilities were identified. The efficacy of immuncheckpoint inhibitor treatment is evidence based not only in metastatic, but in locally advanced disease as well. Successful clinical trials with targeted and immunotherapy in neoadjuvant and in adjuvant settings are underway in early stage non-small cell lung cancer as well. Taking into account content limitations we provide non exhaustive information about the new treatment possibilities in the treatment of non-small cell lung cancer.